Premium
Cannabinoids
for Research

Morphine Sulfate is a naturally occurring opiate alkaloid derived from the opium poppy (Papaver somniferum) and represents the principal active constituent of opium. First isolated in 1804 by Friedrich Sertürner, it has over two centuries of documented scientific study and remains the benchmark reference compound in opioid receptor pharmacology. Morphine acts as a full agonist at mu-opioid receptors (MOR) and to a lesser extent at kappa and delta opioid receptors. It engages Gi/Go-coupled signalling pathways, inhibiting adenylyl cyclase activity and modulating ion channel conductance. Its receptor binding profile is the standard against which all other opioid compounds are evaluated in pharmacological research. The sulfate salt form provides superior aqueous solubility and chemical stability compared to the free base, making it ideal for in vitro and in vivo research formulations. Our Morphine Sulfate is produced to a minimum purity of 99%+, confirmed by HPLC and NMR spectroscopy. It is widely used as a certified reference standard in analytical chemistry, receptor binding assays, pharmacokinetic modelling, and pain research. A full Certificate of Analysis (CoA) with spectral data is included with every order.

Diacetylmorphine, commonly referred to as heroin, is the 3,6-diacetyl ester derivative of morphine. It was first synthesised in 1874 by C.R. Alder Wright at St. Bartholomew's Hospital in London and later commercially developed by Bayer AG in Germany in 1898. It is one of the most extensively studied opioid compounds in addiction neuroscience and pharmacokinetic research. Diacetylmorphine is a prodrug that undergoes rapid deacetylation in vivo, first to 6-monoacetylmorphine (6-MAM) and subsequently to morphine — both active opioid receptor agonists. The acetylation of morphine significantly increases the compound's lipophilicity, which accelerates its passage across lipid barriers and alters its pharmacokinetic profile compared to morphine. These metabolic conversion pathways make it a key study compound in prodrug pharmacology, opioid metabolism research, and addiction biology. Our diacetylmorphine is manufactured to 99%+ purity, verified by HPLC-MS and NMR analysis. It is used as an analytical reference standard in forensic toxicology, metabolism studies, and opioid receptor pharmacology research. Each batch is supplied with a comprehensive Certificate of Analysis.

Oxycodone Hydrochloride is a semi-synthetic opioid analgesic first synthesised in Germany in 1916 by Martin Freund and Edmund Speyer at the University of Frankfurt. It is derived from thebaine, an alkaloid of the opium poppy, and belongs to the phenanthrene class of opioid compounds. Oxycodone functions as a full agonist at mu-opioid receptors (MOR) with additional activity at kappa and delta receptors. Its oral bioavailability of 60–87% and predictable pharmacokinetic profile distinguish it from other opioids and have made it a widely used comparator compound in opioid pharmacology studies. Oxycodone's receptor binding kinetics, metabolic pathway via CYP3A4 and CYP2D6, and its active metabolites — including oxymorphone — are thoroughly documented in peer-reviewed literature. Our Oxycodone HCl is produced to 99%+ purity, verified by HPLC-UV and NMR spectroscopy. The hydrochloride salt provides excellent aqueous solubility suitable for in vitro research formulations. Applications include opioid receptor pharmacology, analytical reference standards, pharmacokinetic studies, and abuse-deterrent formulation research. A complete Certificate of Analysis is included with every order.

Fentanyl Citrate is a synthetic opioid of the 4-anilidopiperidine class, first synthesised in 1960 by Belgian chemist Paul Janssen at Janssen Pharmaceutica. It is among the most extensively studied synthetic opioids in the scientific literature, with applications spanning anaesthesiology research, receptor pharmacology, and opioid analgesic development. Fentanyl is a selective mu-opioid receptor (MOR) full agonist. Its high lipophilicity enables rapid distribution across physiological membranes, producing a pharmacokinetic profile characterised by fast onset and a duration determined by redistribution rather than metabolism. These distinct pharmacokinetic properties make it a valuable comparator compound in opioid pharmacokinetic studies. Fentanyl's interaction with both G-protein and beta-arrestin signalling pathways at the MOR has also made it central to biased agonism research in opioid pharmacology. The citrate salt form (molecular formula C₂₂H₂₈N₂O·C₆H₈O₇) offers greatly improved aqueous solubility. Our Fentanyl Citrate is produced to 99%+ purity, confirmed by HPLC-MS, NMR spectroscopy, and elemental analysis. It is used as a certified reference standard in forensic toxicology, analytical chemistry, receptor binding assays, and anaesthesiology research. A full Certificate of Analysis is provided with every batch.

Isotonitazene is a synthetic opioid compound belonging to the 2-benzylbenzimidazole (nitazene) class. The nitazene series was originally developed by researchers at CIBA Pharmaceutical Company in Switzerland during the 1950s and 1960s as part of a systematic investigation into novel non-morphine analgesic scaffolds. Isotonitazene is characterised by an isopropyl substituent at the benzimidazole nitrogen and an N,N-diethylaminoethyl side chain. Isotonitazene is a full agonist at mu-opioid receptors and has been the subject of extensive analytical characterisation since its appearance in forensic and pharmacological literature. Its receptor binding properties, metabolic profile, and physicochemical characteristics have been documented and are available in scientific reference databases. The compound's pharmacological potency within the nitazene series has been quantified in several peer-reviewed receptor binding studies, making it an important reference point for structure-activity relationship (SAR) research in the 2-benzylbenzimidazole opioid class. Our Isotonitazene is produced to 99%+ purity, confirmed by HPLC-MS and multinuclear NMR analysis. Each batch includes a full Certificate of Analysis with complete spectroscopic data. It is used in opioid receptor pharmacology, forensic reference standard development, analytical method validation, and comparative SAR studies of the benzimidazole opioid series.

Metonitazene is a synthetic opioid of the 2-benzylbenzimidazole (nitazene) class, structurally distinguished by a methoxy substituent at the para position of the benzyl phenyl ring. Like other nitazene compounds, it originates from mid-20th century pharmaceutical research at CIBA Pharmaceutical Company in Switzerland. Metonitazene functions as a full mu-opioid receptor agonist. Within the nitazene structure-activity relationship (SAR) literature, the para-methoxy substitution at the benzyl phenyl ring has been identified as a key determinant of receptor binding affinity relative to unsubstituted analogues. In vitro metabolic studies using human liver microsomes have characterised its primary metabolic routes, including N-dealkylation and O-demethylation, providing data of value in pharmacokinetic and forensic research. Our Metonitazene is produced to 99%+ purity, confirmed by HPLC-MS, ¹H NMR, ¹³C NMR, and elemental analysis. Full spectroscopic documentation and a Certificate of Analysis are provided with every batch. Primary applications include opioid receptor pharmacology, benzimidazole SAR research, forensic reference material development, and analytical method validation.